TLDR
AstraZeneca stock climbs 7% as revenue reaches $46.9 billion in nine months.
AstraZeneca core EPS rises 14% to $8 as nine-month operating profit increases.
Oncology revenue grows 16% to $21.9 billion, leading AstraZeneca’s therapy areas.
AstraZeneca secures 47 regional approvals, including four newly approved medicines.
AstraZeneca maintains 2026 guidance as its 2027 pipeline targets exceed $20 billion.
AstraZeneca PLC (AZN) stock climbed 7.02% to $186.65, adding $12.25 during the trading session. The advance followed strong nine-month financial results, with revenue and core earnings recording solid growth. Additionally, the pharmaceutical company reported new medicine approvals and positive clinical results, strengthening its development pipeline.
AstraZeneca PLC, AZN
AstraZeneca Reports Higher Revenue and Earnings in 9M 2026
AstraZeneca generated $46.9 billion in total revenue during the first nine months of 2026. The figure represented 7% growth at constant exchange rates, while product revenue reached $46.8 billion. Meanwhile, alliance revenue increased 33% to $2.8 billion, supporting the company’s overall revenue performance.
Core operating profit increased 14% to $16.4 billion during the reporting period. Similarly, core earnings per share reached $8.00, marking a 14% increase at constant exchange rates. Reported earnings per share also improved, rising 11% to $5.62 on a constant currency basis.
The third quarter contributed $16.2 billion in total revenue, representing 7% growth at constant exchange rates. Product revenue reached $16.17 billion, while alliance revenue increased 36% to $1.11 billion. Furthermore, core EPS climbed 19% to $2.79, while reported EPS increased 26% to $2.02.
Oncology and Rare Disease Lead Therapy Area Growth
Oncology remained AstraZeneca’s largest therapy area, generating $21.9 billion during the first nine months. The division accounted for 47% of total revenue and recorded 16% growth at constant exchange rates. Consequently, oncology provided the largest contribution among the company’s reported therapy areas.
Rare Disease generated $7.5 billion, representing 16% of total revenue during the period. The division recorded 11% growth at constant exchange rates, reflecting continued expansion across its business. However, BioPharmaceuticals revenue declined 5% to $16.7 billion, accounting for 36% of total revenue.
Within BioPharmaceuticals, Respiratory and Immunology revenue increased 10% during the reporting period. Conversely, Cardiovascular, Renal and Metabolism revenue fell 14%, while Infectious Disease declined 12%. These contrasting results reflected different performance trends across AstraZeneca’s established treatment categories.
New Medicine Approvals and 2026 Guidance Support Growth Plans
AstraZeneca secured 47 approvals across major regions following its fourth-quarter 2025 results. The approvals included four new medicines, namely Etcamah, Baxfendy, Klygefa and Amlypave. Additionally, the company reported 12 positive Phase III programme readouts with substantial potential commercial value.
The company also announced first Phase III data for three new molecular entities. These included tozorakimab, efzimfotase alfa and sonesitatug vedotin, expanding its late-stage development portfolio. Their combined development progress adds to a pipeline supporting AstraZeneca’s longer-term commercial plans.
AstraZeneca maintained its full-year 2026 financial guidance following the nine-month results. At constant exchange rates, the company expects total revenue to increase by a mid-to-high single-digit percentage. Furthermore, it projects low double-digit growth in core EPS and expects its core tax rate between 18% and 22%.
The company also identified substantial revenue potential across its upcoming clinical programmes. Its 2027 readouts carry potential peak annual revenue exceeding $20 billion, according to its outlook. Meanwhile, AstraZeneca continues to target its 2030 ambition through late-stage medicines and developing technologies.
The post AstraZeneca PLC (AZN) Stock : Jumps 7% as Revenue Rises 7% and Core EPS Gains 14% appeared first on Blockonomi .
